Fresenius Medical Care AG
DUS:FME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Fresenius Medical Care AG (FME) under the Base Case is 42.26 EUR per share.
Compared with the current market price of 41.12 EUR, the stock appears
Undervalued by 3% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Fresenius Medical Care Does
Fresenius Medical Care AG is one of the world’s main kidney care companies. It treats patients with chronic kidney failure by running dialysis clinics and by providing dialysis treatments in hospitals and care centers. It also sells the equipment, filters, and related supplies needed to deliver dialysis, which makes it both a care provider and a medical products supplier.
- Headquarters
- Germany DE
- Employees
- 123 106
- IPO date
- Oct 2, 1996
Fresenius Medical Care has no economic moat
In much of the U.S., government reimbursement and competition based on care quality, access, and physician referrals leave little evidence that the Fresenius name lets the company charge more. Patients and doctors can choose other dialysis providers, and Fresenius’s scale does not make its services more valuable simply because more people use them.
Read the full moat analysis
Revenue & Expenses Breakdown
Fresenius Medical Care AG
Earnings Waterfall
Fresenius Medical Care AG
What is the Intrinsic Value of one FME stock?
The intrinsic value for Fresenius Medical Care AG (FME) under the Base Case is 42.26 EUR.
Is FME stock undervalued or overvalued?
Compared with the current market price of 41.12 EUR, the stock appears Undervalued by 3% .
